Assaf Ezra

581 total citations · 1 hit paper
16 papers, 424 citations indexed

About

Assaf Ezra is a scholar working on Molecular Biology, Immunology and Neurology. According to data from OpenAlex, Assaf Ezra has authored 16 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Immunology and 3 papers in Neurology. Recurrent topics in Assaf Ezra's work include RNA Interference and Gene Delivery (5 papers), Alzheimer's disease research and treatments (3 papers) and Advanced biosensing and bioanalysis techniques (3 papers). Assaf Ezra is often cited by papers focused on RNA Interference and Gene Delivery (5 papers), Alzheimer's disease research and treatments (3 papers) and Advanced biosensing and bioanalysis techniques (3 papers). Assaf Ezra collaborates with scholars based in Israel, United Kingdom and Italy. Assaf Ezra's co-authors include Gonna Somu Naidu, Beka Solomon, Inna Rabinovich-Nikitin, Dan Peer, Meir Goldsmith, Inbal Hazan‐Halevy, Srinivas Ramishetti, Sushmita Chatterjee, Seok‐Beom Yong and Riccardo Rampado and has published in prestigious journals such as Advanced Materials, Nano Letters and ACS Nano.

In The Last Decade

Assaf Ezra

16 papers receiving 419 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors

2025 21 citations Gonna Somu Naidu, Riccardo Rampado et al. ACS Nano profile →

Peers

Countries citing papers authored by Assaf Ezra

Since Specialization

Citations

This map shows the geographic impact of Assaf Ezra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Assaf Ezra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Assaf Ezra more than expected).

Fields of papers citing papers by Assaf Ezra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Assaf Ezra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Assaf Ezra. The network helps show where Assaf Ezra may publish in the future.

Co-authorship network of co-authors of Assaf Ezra

This figure shows the co-authorship network connecting the top 25 collaborators of Assaf Ezra. A scholar is included among the top collaborators of Assaf Ezra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Assaf Ezra. Assaf Ezra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles 2025 ·Small ·Shai Zilberzwige‐Tal, Aviad Levin, Assaf Ezra, Uri Elia, (unknown), (unknown), (unknown), Meir Goldsmith, Edo Kon, (unknown), Ofer Cohen, Tuomas P. J. Knowles, Dan Peer, Ehud Gazit	1
2	Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors breakdown → 2025 ·ACS Nano ·Gonna Somu Naidu, Riccardo Rampado, (unknown), Assaf Ezra, (unknown), (unknown), Dan Peer	21
3	Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer 2024 ·Advanced Science ·(unknown), (unknown), Lior Stotsky‐Oterin, Nitay Ad‐El, (unknown), Gonna Somu Naidu, (unknown), Assaf Ezra, Meir Goldsmith, Inbal Hazan‐Halevy, Dan Peer	11
4	Targeting phenylalanine assemblies as a prospective disease-modifying therapy for phenylketonuria 2024 ·Biophysical Chemistry ·Shira Shaham‐Niv, Assaf Ezra, Dor Zaguri, (unknown), (unknown), Hamutal Engel, (unknown), (unknown), Haim Barr, Lihi Adler‐Abramovich, Ehud Gazit	3
5	Lipid Nanoparticles With Fine‐Tuned Composition Show Enhanced Colon Targeting as a Platform for mRNA Therapeutics 2024 ·Advanced Science ·Riccardo Rampado, Gonna Somu Naidu, (unknown), Meir Goldsmith, (unknown), Assaf Ezra, (unknown), (unknown), Dan Peer	10
6	A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery 2023 ·Advanced Science ·Gonna Somu Naidu, Seok‐Beom Yong, Srinivas Ramishetti, Riccardo Rampado, (unknown), Assaf Ezra, Meir Goldsmith, Inbal Hazan‐Halevy, Sushmita Chatterjee, (unknown), Dan Peer	73
7	A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium 2023 ·Science Advances ·Edo Kon, Yinon Levy, Uri Elia, Hagai Cohen, Inbal Hazan‐Halevy, Moshe Aftalion, Assaf Ezra, Erez Bar‐Haim, Gonna Somu Naidu, Yael Diesendruck, Shahar Rotem, Nitay Ad‐El, Meir Goldsmith, Emanuelle Mamroud, Dan Peer, Ofer Cohen	61
8	Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors 2023 ·Theranostics ·(unknown), Assaf Ezra, Srinivas Ramishetti, (unknown), Gonna Somu Naidu, Itai Benhar, Dan Peer	12
9	Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells 2023 ·Science Advances ·Sushmita Chatterjee, Gonna Somu Naidu, Inbal Hazan‐Halevy, (unknown), Assaf Ezra, (unknown), Meir Goldsmith, Srinivas Ramishetti, David Sprinzak, Ronen Zaidel‐Bar, Dan Peer	15
10	Dual‐Targeted Lipid Nanotherapeutic Boost for Chemo‐Immunotherapy of Cancer 2022 ·Advanced Materials ·Seok‐Beom Yong, Srinivas Ramishetti, Meir Goldsmith, Yael Diesendruck, Inbal Hazan‐Halevy, Sushmita Chatterjee, Gonna Somu Naidu, Assaf Ezra, Dan Peer	54
11	Dual‐Targeted Lipid Nanotherapeutic Boost for Chemo‐Immunotherapy of Cancer (Adv. Mater. 13/2022) 2022 ·Advanced Materials ·Seok‐Beom Yong, Srinivas Ramishetti, Meir Goldsmith, Yael Diesendruck, Inbal Hazan‐Halevy, Sushmita Chatterjee, Gonna Somu Naidu, Assaf Ezra, Dan Peer	3
12	Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer’s Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers 2020 ·Journal of Alzheimer s Disease ·(unknown), Inna Rabinovich-Nikitin, Assaf Ezra, (unknown), Beka Solomon	19
13	Biocompatible Hybrid Organic/Inorganic Microhydrogels Promote Bacterial Adherence and Eradication in Vitro and in Vivo 2020 ·Nano Letters ·Lee Schnaider, Zenon Toprakcioglu, Assaf Ezra, (unknown), Darya Bychenko, Aviad Levin, Ehud Gazit, Tuomas P. J. Knowles	44
14	Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS 2016 ·Journal of Neuroinflammation ·Inna Rabinovich-Nikitin, Assaf Ezra, (unknown), (unknown), Beka Solomon	39
15	Multifunctional Effect of Human Serum Albumin Reduces Alzheimer’s Disease Related Pathologies in the 3xTg Mouse Model 2016 ·Journal of Alzheimer s Disease ·Assaf Ezra, Inna Rabinovich-Nikitin, (unknown), Beka Solomon	40
16	Mutant SOD1 Increases APP Expression and Phosphorylation in Cellular and Animal Models of ALS 2015 ·PLoS ONE ·(unknown), Inna Rabinovich-Nikitin, Assaf Ezra, (unknown), Hilla Fogel, Inna Slutsky, Beka Solomon	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact